BioCentury

8:00 AM GMT, Feb 28, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Levact regulatory update

The U.K.'s NICE issued final guidance recommending the use of Levact bendamustine from Mundipharma as a first-line treatment for patients with

Read the full 217 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.